In the current study, we evaluate the use of short-acting β-agonist (SABA) prescriptions as a surrogate marker for asthma exacerbation with respect to these more traditional markers. Methods ...

Our results support that the use of β2-agonists should be controlled and restricted to athletes with documented asthma. Systematic review registration PROSPERO CRD42018109223.

is equally effective for improving pulmonary function and reducing symptoms of acute asthma in both adult and pediatric patients (quality of evidence: good). The delivery of β 2-agonists in the ...

The multicenter study randomized 196 patients with poorly controlled asthma despite moderate to high doses of inhaled corticosteroid and long-acting β2 adrenergic agonist (ICS/LABA) treatment.

Do not initiate in rapidly or acutely deteriorating asthma. Not for use with other long-acting β 2-agonists. Do not exceed recommended dose. Prescribe a short-acting, inhaled β 2-agonist for ...

BOSTON -- Inhaled corticosteroids (ICS) combined either with formoterol (Foradil) or short-acting beta-agonists (SABA) for asthma treatment were associated with reduced risks of severe ...